A PILOT STUDY OF DUAL IMMUNOTHERAPY (PD1/CD73) IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH PANCREATIC ADENOCARCINOMA: IMMUNE MECHANISMS OF RESISTANCE
$590,625FY2025Defense Health AgencyDOD
University Of California, Los Angeles
University Of California, Los Angeles